Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer. - Wikidata - awgldk - TriplyDB

Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.

Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.

http://www.wikidata.org/entity/Q54445461

about

Systematic review of peri-operative prognostic biomarkers in pancreatic ductal adenocarcinoma Adjuvant therapy for pancreas cancer in an era of value based cancer care Evolution and dynamics of pancreatic cancer progression Selection criteria in resectable pancreatic cancer: a biological and morphological approach Acquisition of Portal Venous Circulating Tumor Cells From Patients With Pancreaticobiliary Cancers by Endoscopic Ultrasound.The DPC4/SMAD4 genetic status determines recurrence patterns and treatment outcomes in resected pancreatic ductal adenocarcinoma: A prospective cohort study.Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward.Neoadjuvant chemotherapy in borderline resectable pancreatic cancer: A case report.The Impact of SMAD4 Loss on Outcome in Patients with Advanced Pancreatic Cancer Treated with Systemic Chemotherapy Pancreatic biomarkers: could they be the answer?The complex landscape of pancreatic cancer metabolism Role of neoadjuvant therapy in the management of pancreatic cancer: is the era of biomarker-directed therapy here?Translational research in pancreatic ductal adenocarcinoma: current evidence and future concepts.Meta-analysis of the prognostic value of smad4 immunohistochemistry in various cancers.Ploidy and DNA index as prognostic factors in resected pancreatic ductal adenocarcinoma - a review of the literature.Loss of canonical Smad4 signaling promotes KRAS driven malignant transformation of human pancreatic duct epithelial cells and metastasis.Protein deep sequencing applied to biobank samples from patients with pancreatic cancer.Clinical outcome and expression of mutant P53, P16, and Smad4 in lung adenocarcinoma: a prospective study ERK kinase phosphorylates and destabilizes the tumor suppressor FBW7 in pancreatic cancer Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer.Minimally Invasive Pancreaticoduodenectomy Does Not Improve Use or Time to Initiation of Adjuvant Chemotherapy for Patients With Pancreatic Adenocarcinoma.Immunohistochemical Typing of Adenocarcinomas of the Pancreatobiliary System Improves Diagnosis and Prognostic Stratification The evolution of tumor metastasis during clonal expansion with alterations in metastasis driver genes Safety and Biologic Response of Pre-operative Autophagy Inhibition in Combination with Gemcitabine in Patients with Pancreatic Adenocarcinoma.Mutant p53 determines pancreatic cancer poor prognosis to pancreatectomy through upregulation of cavin-1 in patients with preoperative serum CA19-9 ≥ 1,000 U/mL.Neoadjuvant treatment for resectable pancreatic adenocarcinoma.Prognostic Value of SMAD4 in Pancreatic Cancer: A Meta-Analysis.The prognostic role of desmoplastic stroma in pancreatic ductal adenocarcinoma Smad4 inhibits cell migration via suppression of JNK activity in human pancreatic carcinoma PANC-1 cells Serum CA125 is a novel predictive marker for pancreatic cancer metastasis and correlates with the metastasis-associated burden.Prognostic Value of Metabolic and Volumetric Parameters of Preoperative FDG-PET/CT in Patients With Resectable Pancreatic Cancer.ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer.Cdc7 is a potent anti-cancer target in pancreatic cancer due to abrogation of the DNA origin activation checkpoint Maximum Standard Uptake Value as a Clinical Biomarker for Detecting Loss of SMAD4 Expression and Early Systemic Tumor Recurrence in Resected Left-Sided Pancreatic Cancer.Molecular, morphological and survival analysis of 177 resected pancreatic ductal adenocarcinomas (PDACs): Identification of prognostic subtypes.Germline mutations in Japanese familial pancreatic cancer patients.Clinicopathological significance of SMAD4 loss in pancreatic ductal adenocarcinomas: a systematic review and meta-analysis.Prognostic factors related with survival in patients with pancreatic adenocarcinoma Genome-wide DNA methylation analysis reveals molecular subtypes of pancreatic cancer.Diagnostic value of selected markers and apoptotic pathways for pancreatic cancer.

P2860

Q26739910-FEA79BEA-3DD7-4D9F-A845-DA76FA5276AD Q26775916-5EC2C432-EBA7-40C1-A89A-9759212D016B Q26849671-FF8E7247-CB63-4D73-BE8C-00E55966F245 Q26859742-811200B0-FF73-423D-94C2-A7D232BB9E13 Q30376511-3518392F-5861-4D2E-A2E9-003A2B40C65A Q33566753-4A0637F0-A703-4EDC-9AF1-4C7792D738DA Q33624574-FA5FACFA-2A9F-47F3-914F-4CD43FCADE1E Q33750803-39D936B0-069B-4FF9-A643-07939CA2A19A Q33755454-57F5058E-9530-46AB-A3F3-BB15AAEA3839 Q33801371-63CD8903-A64D-41B5-9B52-88A84038DA9F Q33827703-A29B9184-2AE4-4AAF-8482-3E5BDB10FD91 Q33982773-CA69B056-EB53-4364-B251-C782D9384D63 Q34067863-8589A7D8-AC8B-40B2-A917-CE15B0322EEC Q34344060-E87EBE41-939A-4D17-8805-532FB5643753 Q34990040-9201E3BE-7073-4684-9CF5-B570C9DC8208 Q35080923-F8051BBF-EFD7-440A-844C-61DFA1743C75 Q35250650-56C2CFED-96A1-4F81-B080-26FBDF65A864 Q35556136-513432EF-9261-424D-8828-431F2A39CB23 Q35578938-261C66E8-992A-4091-8B1D-98F3D24241B2 Q35671422-66FD536C-ACB9-4E15-A6C7-1209BC5E7A2F Q35834208-B0E632E7-D981-4130-82AF-2FB5606BA6E3 Q36187546-B4F38BD2-13D6-4E3A-A8FE-F7132ED53ED4 Q36227108-5159B226-03E7-4E32-AE4F-257CF2CB35A9 Q36329393-D8DD2F69-EF39-47B4-A6FA-944753C572E5 Q36453968-EB2C39B4-2367-42B3-AE70-F0E08F4DA89C Q36526141-32838AFF-62E0-488A-AF43-E1CE0E7E5F76 Q36707119-5B874A3C-33BB-41C2-A7CD-6699CE374A8B Q36782384-74B227D3-77D1-427F-B8F2-524C0565773D Q36825201-ABACB396-E7EB-480B-A0FE-7A8B54A10F4A Q36905807-604847A1-E6DE-4371-B15A-F6870D45634B Q36993625-45C8C95A-0D29-468B-99C0-2B98ADF87108 Q37030917-BC004943-4F70-4BED-ADBB-BAF0BD99E39F Q37109795-9F84875E-EC69-4C4E-8343-6E65659D0EDC Q37206394-742E04B2-AB62-4E94-BB3C-48B7C97CB7FF Q37618295-68C84D69-0D33-4D12-A8AC-0BFC19B6DE91 Q37687547-5FDAAA02-E452-440A-A1E8-974BAF8AD86C Q37725506-892436C1-AAB6-4FAD-A9C5-D1D736744332 Q38242807-DE577411-1E0B-4072-BB3A-132311D8C83B Q38693071-F231A9A7-F96E-464D-BD6D-17CD0945B5A3 Q38815842-2D9ED638-766A-4CD0-94F0-A2911F7FCBB2

P2860

Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.

http://www.wikidata.org/entity/Q54445461

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Immunohistochemically detected ...... resectable pancreatic cancer.

@en

Immunohistochemically detected ...... resectable pancreatic cancer.

@nl

type

label

Immunohistochemically detected ...... resectable pancreatic cancer.

@en

Immunohistochemically detected ...... resectable pancreatic cancer.

@nl

prefLabel

Immunohistochemically detected ...... resectable pancreatic cancer.

@en

Immunohistochemically detected ...... resectable pancreatic cancer.

@nl

P1433

Q54445461-0786AA05-9877-4C8D-ABA3-DB33B4EF0442

P1476

Q54445461-E7606E6C-1ACF-494D-B65C-E6DEEB4CEB63

P2093

Q54445461-40120DAC-D38E-4930-A49D-DA567814A550

Q54445461-54FEFC2A-4029-4751-A9B3-76AC745C8A66

Q54445461-56082799-AA38-4946-9AF8-0829E065A909

Q54445461-58928F79-DD07-40EC-8856-A96736164843

Q54445461-BDF8E48C-CA40-4F93-9F70-4F40644499B7

Q54445461-C8925C57-5F5F-41D8-A0F5-BCD90506FEDD

Q54445461-CE12020B-C70C-44F9-A6D3-62F0575F415F

P304

Q54445461-BE6C2D20-4EF3-42B3-946E-E3AC5D9B9A34

P31

Q54445461-BA821236-7AF4-4D35-8E77-98DCC9B24F69

P356

Q54445461-3492D662-4667-4D6A-B0BC-83AF974F1F5B

P407

Q54445461-67ED8FA4-0E15-49DB-98B1-E7BF7E8F6C49

P433

Q54445461-F3E5AD7B-DF04-457F-BDCE-29DBC16324CB

P478

Q54445461-926A20FA-BA17-450B-83D7-758294F3E4FB

P577

Q54445461-E5923E1F-5E3B-4BA2-B055-8BC5553FE009

P698

Q54445461-5E29542D-D881-4769-B52C-D3CE3F487EC7

P921

Q54445461-23F00CA7-4B17-4A66-9C32-98593C8B0E6A

Q54445461-DB4C74AC-87B7-48B3-AEB9-2F9EC8E8BF6E

P356

SLA.0B013E3182827A65

P1433

Annals of Surgery

P1476

Immunohistochemically detected ...... resectable pancreatic cancer.

@en

P2093

Keiichi Okano

http://www.w3.org/2001/XMLSchema#string

Minoru Oshima

http://www.w3.org/2001/XMLSchema#string

Reiji Haba

http://www.w3.org/2001/XMLSchema#string

Shinichi Yachida

http://www.w3.org/2001/XMLSchema#string

Shinobu Muraki

http://www.w3.org/2001/XMLSchema#string

Takashi Maeba

http://www.w3.org/2001/XMLSchema#string

Yasuyuki Suzuki

http://www.w3.org/2001/XMLSchema#string

P304

336-346

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/SLA.0B013E3182827A65

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

258

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23470568

http://www.w3.org/2001/XMLSchema#string

P921

immunohistochemistry